About this trial
The main purpose of this trial is to determine whether the addition of the VIEWER virtual care platform to usual care will lead to a reduction in composite emergency department (ED) visits and/or hospitalizations/or increase the perceived safety of virtual care among patients and providers.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
>18 years of age
Patient or primary caregiver can read and speak English
Patient or patients substitute decision maker is able to provide informed consent
Patient or primary care giver cognitively and physically capable and willing to use the VIEWER mobile application and perform self-measurements (i.e. weight, BP, etc.)
Disqualifiers
Inability of self or caregiver assisted self-monitoring using VIEWER
Trial design
Parallel
Treatments tested in this trial
VIEWER virtual care platform
DeviceVIEWER is a tablet based, CKD specific home telemonitoring platform developed by our team of patients and researchers that integrates data from a wireless blood pressure cuff, weigh scale, transcutaneous O2 sat monitor and wearable motion tracker via a tablet and custom app.
Treatment groups
Trial outcomes
Primary outcomes
Composite of first hospitalization or emergency department (ED) visit
It's defined as an inpatient admission to hospital or a visit to the emergency department, whatever is first". So, we will compare the time of the first hospital admission /and or ED visit between two groups.
Secondary outcomes
All-cause mortality
The mortality rate will be compared between the intervention and control group.
Proportion of patients who have an acute inpatient initiation of dialysis.
the rate of patients who started dialysis in the intervention and control groups during 1 year of follow-up.
Frequency of Emergency Department Visit
The average frequency of ED visit will be compared in two study groups.
Frequency of formal clinic visits
The average frequency of formal clinic visits will be compared between two study groups
Sponsors and contacts
Click on the lead sponsor to view all of their trials.